Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2 - 22/07/20
Doi : 10.1016/j.jaci.2020.04.009
Daniel J. Jackson, MD a 
, William W. Busse, MD a, Leonard B. Bacharier, MD b, Meyer Kattan, MD c, George T. O’Connor, MD d, Robert A. Wood, MD e, Cynthia M. Visness, PhD f, Stephen R. Durham, MD g, David Larson, PhD h, Stephane Esnault, PhD a, Carole Ober, PhD i, Peter J. Gergen, MD j, Patrice Becker, MD j, Alkis Togias, MD j, James E. Gern, MD a, Mathew C. Altman, MD k, l
, William W. Busse, MD a, Leonard B. Bacharier, MD b, Meyer Kattan, MD c, George T. O’Connor, MD d, Robert A. Wood, MD e, Cynthia M. Visness, PhD f, Stephen R. Durham, MD g, David Larson, PhD h, Stephane Esnault, PhD a, Carole Ober, PhD i, Peter J. Gergen, MD j, Patrice Becker, MD j, Alkis Togias, MD j, James E. Gern, MD a, Mathew C. Altman, MD k, l a University of Wisconsin School of Medicine and Public Health, Madison, Wis
b Washington University School of Medicine, Washington University School of Medicine, St Louis, Mo
c Columbia University College of Physicians and Surgeons, New York, NY
d Boston University School of Medicine, Boston, Mass
e Johns Hopkins University School of Medicine, Baltimore, Md
f Rho, Inc, Durham, NC
g Imperial College London and Asthma UK Centre in Allergic Mechanisms of Asthma, London, United Kingdom
h Immune Tolerance Network, Bethesda, Md
i University of Chicago, Chicago, Ill
j National Institute of Allergy and Infectious Disease, Bethesda, Md
k Department of Medicine, University of Washington, Seattle, Wash
l Benaroya Research Institute, Systems Immunology Division, Seattle, Wash
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.
Si connetta per beneficiarne
| This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Department of Health and Human Services, under grant numbers 1UM1AI114271-01, UM2AI117870, 5UM1AI114271-03, and UM1AI109565. Additional support was provided by the National Heart, Lung, and Blood Institute, NIH, through grant number RO1HL12384, and National Center for Advancing Translational Sciences, NIH, through grant numbers UL1TR001079, 1UL1TR001430, UL1TR001873, and UL1TR002345. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. The co-authorship by Drs Gergen, Becker, and Togias on this publication does not necessarily constitute endorsement by the National Institute of Allergy and Infectious Diseases, the NIH or any other agency of the United States government. |
|
| Disclosure of potential conflict of interest: D. J. Jackson reports grants from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)/National Heart, Lung and Blood Institute (NHLBI) and GlaxoSmithKline, as well as personal fees from Pfizer for data and safety and monitoring board participation and personal consulting fees from Novartis, Sanofi-Regeneron, GlaxoSmithKline, Vifor Pharma, and AstraZeneca. W. W. Busse reports grants from the NIH/NIAID/NHLBI during the conduct of the study, as well as personal fees from Novartis, Sandoz, Regeneron, AstraZeneca, GlaxoSmithKline, Genentech, Teva, Elsevier, Arrowhead, resTORbio, Med Learning Group, Practicing Clinicians Exchange, Boston Scientific, and Medscape. L. B. Bacharier reports grant support from the NIH/NIAID/NHLBI, Sanofi, and Vectura, as well as personal fees from GlaxoSmithKline, Genentech, Novartis, Merck, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape, Sanofi, Regeneron, Vectura, and Circassia. R. A. Wood receives grant support from the NIH, Astellas, Aimmune, DBV, Sanofi, and Regeneron, as well as royalties from Up To Date. J. E. Gern reports grants from the NIH; personal fees and stock options from Meissa Vaccines, Inc; personal fees from AstraZeneca and Ena Therapeutics; and a patent on methods for production of rhinoviruses. Dr. Altman reports personal fees from Regeneron for consulting. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2020
American Academy of Allergy, Asthma & Immunology. Tutti i diritti riservati.
Vol 146 - N° 1
P. 203 - Luglio 2020 Ritorno al numero
Articolo precedente
- Hypomorphic variants in AK2 reveal the contribution of mitochondrial function to B-cell activation
- Janet Chou, Anas M. Alazami, Faris Jaber, Rodrigo Hoyos-Bachiloglu, Jennifer Jones, Sabrina Weeks, Mohammed F. Alosaimi, Wayne Bainter, Brittney Cangemi, Yousef R. Badran, Reem Mohammed, Fayhan Alroqi, Abduarahman Almutairi, Noufa Al-Onazi, Sulaiman AlAjaji, Bander Al-Saud, Rand Arnaout, Megan Elkins, Sridevi Devana, Juliet Imperial, Betty Li, Linnea Drexhage, Anas M. Abdel Rahman, Minnie Jacob, Hadi Haddad, Rima Hanna-Wakim, Ghassan Dbaibo, Michel J. Massaad, Majed Dasouki, Raymond Mikhael, Zeina Baz, Raif S. Geha, Hamoud Al-Mousa
- Type I IFN immunoprofiling in COVID-19 patients
- Sophie Trouillet-Assant, Sebastien Viel, Alexandre Gaymard, Sylvie Pons, Jean-Christophe Richard, Magali Perret, Marine Villard, Karen Brengel-Pesce, Bruno Lina, Mehdi Mezidi, Laurent Bitker, Alexandre Belot, COVID HCL Study group, William Mouton, Guy Oriol, Christelle Compagnon, Laurence Generenaz, Valérie Cheynet, Florence Ader, Agathe Becker, Nicholas Benech, Pierre Chauvelot, Christian Chidiac, Anne Conrad, Tristan Ferry, Patrick Miailhes, Thomas Perpoint, Marielle Perry, Cécile Pouderoux, Sandrine Roux, Claire Triffault-Fillit, Florent Valour, Yonis Hodane, Louis Chauvelot, Paul Chabert, Judith Provoost, Guillaume David, Laure Folliet, Pierre Lecam, Geneviève Billaud, Maude Bouscambert, Vanessa Escuret, Emilie Frobert, Antonin Bal, Grégory Destras, Laurence Josset, Florence Morfin, Clément Munier, Martine Valette, Fabienne Venet, Lorna Garnier, Rémi Pescarmona, Christine Lombard, Thierry Walzer
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.